Shattuck Labs to Present at 39th Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Shattuck Labs, a clinical-stage biotechnology company focused on bi-functional fusion proteins for cancer and autoimmune disease treatment, will present at the 39th Annual J.P. Morgan Healthcare Conference from January 11-14, 2021. CEO Taylor Schreiber will speak on January 14 at 5:20 p.m. EST. The presentation can be accessed live via webcast, with a replay available for 30 days. Shattuck's lead program is SL-172154, currently in Phase 1 trials, aiming to block the CD47 immune checkpoint while activating the CD40 pathway.

AUSTIN, TX and DURHAM, NC, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced it will present at the 39^th Annual J.P. Morgan Healthcare Conference being held virtually January 11-14, 2021.

Presentation Details
Conference: 39th Annual J.P. Morgan Healthcare Conference
Presenter: Taylor Schreiber, M.D., Ph.D., Shattuck’s Chief Executive Officer
Date: January 14, 2021
Time: 5:20 p.m. EST
Webcast Link: Available Here

The live webcast of the presentation will be available on the Events & Presentations section of the Company’s website. A replay of the webcast will be archived for up to 30 days following the presentation date.

About Shattuck Labs, Inc.
Shattuck is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck’s proprietary Agonist Redirected Checkpoint, ARC^®, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. The company’s lead wholly owned program, SL-172154 (SIRPα-Fc-CD40L), which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in a Phase 1 trial. A second compound, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in collaboration with Takeda Pharmaceuticals. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager, GADLEN™, platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer. Shattuck has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com.

Investor Contact:
Conor Richardson
Senior Director, Finance & Investor Relations
Shattuck Labs, Inc.
InvestorRelations@shattucklabs.com

Media Contact:
Stephanie Ascher
Managing Director
Stern Investor Relations, Inc.
Stephanie.ascher@sternir.com

FAQ

When will Shattuck Labs present at the J.P. Morgan Healthcare Conference?

Shattuck Labs will present on January 14, 2021, at 5:20 p.m. EST.

Who is presenting for Shattuck Labs at the conference?

Taylor Schreiber, CEO of Shattuck Labs, will be presenting.

What is the webcast link for Shattuck Labs' presentation?

The webcast link for the presentation can be found on the company's website.

What is the focus of Shattuck Labs' research?

Shattuck Labs focuses on developing bi-functional fusion proteins for cancer and autoimmune diseases.

What is the ticker symbol for Shattuck Labs?

The ticker symbol for Shattuck Labs is STTK.

What are the lead programs being evaluated by Shattuck Labs?

Shattuck Labs is evaluating SL-172154 and SL-279252 in Phase 1 trials.